Risk management and statistical multivariate analysis approach for design and optimization of satranidazole nanoparticles.
Rapidly evolving technical and regulatory landscapes of the pharmaceutical product development necessitates risk management with application of multivariate analysis using Process Analytical Technology (PAT) and Quality by Design (QbD). Poorly soluble, high dose drug, Satranidazole was optimally nanoprecipitated (SAT-NP) employing principles of Formulation by Design (FbD). The potential risk factors influencing the critical quality attributes (CQA) of SAT-NP were identified using Ishikawa diagram. Plackett-Burman screening design was adopted to screen the eight critical formulation and process parameters influencing the mean particle size, zeta potential and dissolution efficiency at 30min in pH7.4 dissolution medium. Pareto charts (individual and cumulative) revealed three most critical factors influencing CQA of SAT-NP viz. aqueous stabilizer (Polyvinyl alcohol), release modifier (Eudragit® S 100) and volume of aqueous phase. The levels of these three critical formulation attributes were optimized by FbD within established design space to minimize mean particle size, poly dispersity index, and maximize encapsulation efficiency of SAT-NP. Lenth's and Bayesian analysis along with mathematical modeling of results allowed identification and quantification of critical formulation attributes significantly active on the selected CQAs. The optimized SAT-NP exhibited mean particle size; 216nm, polydispersity index; 0.250, zeta potential; -3.75mV and encapsulation efficiency; 78.3%. The product was lyophilized using mannitol to form readily redispersible powder. X-ray diffraction analysis confirmed the conversion of crystalline SAT to amorphous form. In vitro release of SAT-NP in gradually pH changing media showed <20% release in pH1.2 and pH6.8 in 5h, while, complete release (>95%) in pH7.4 in next 3h, indicative of burst release after a lag time. This investigation demonstrated effective application of risk management and QbD tools in developing site-specific release SAT-NP by nanoprecipitation.
School of Pharmaceutical Sciences, Jaipur National University, Jaipur, Rajasthan 302017, India; Department of Pharmaceutics, S.T.E.S's Sinhgad Institute of Pharmacy, Narhe, Pune, Maharashtra 411041, India. Electronic address: shalakapd@gmail.com.
Shalaka
S
Dhat
Department of Biosciences and Bioengineering, Indian Institute of Technology, Powai, Mumbai 400076, India.
Swati
S
Pund
Department of Pharmaceutics, S.T.E.S's Sinhgad Institute of Pharmacy, Narhe, Pune, Maharashtra 411041, India.
Chandrakant
C
Kokare
School of Pharmaceutical Sciences, Jaipur National University, Jaipur, Rajasthan 302017, India.
Pankaj
P
Sharma
School of Pharmaceutical Sciences, Jaipur National University, Jaipur, Rajasthan 302017, India.
Birendra
B
Shrivastava
D015195:Drug Design; D008962:Models, Theoretical; D015999:Multivariate Analysis; D053758:Nanoparticles / Q000737:chemistry*; D009593:Nitroimidazoles / Q000737:chemistry*; D010316:Particle Size; D012308:Risk Management / Q000706:statistics & numerical data*
D009593:Nitroimidazoles; C034473:satranidazole
Design of experiments; Formulation by design; Ishikawa diagram; Plackett-Burman; Risk assessment